A Study of Azidothymidine (AZT) in the Treatment of HIV Infection in Patients Receiving a Bone Marrow Transplant

A Pilot Study To Evaluate Azidothymidine (AZT) in the Treatment of Human Immunodeficiency Virus (HIV) Infection in Patients Receiving a Bone Marrow Transplant

To determine whether zidovudine (AZT) in conjunction with bone marrow transplantation prevents the reinfection of donor hematopoietic/lymphoid cells in patients with positive HTLV III antibody and large cell/diffuse histiocytic lymphoma. Patients who are candidates will be evaluated for HTLV III activity and drug levels.

Exclusion Criteria

Co-existing Condition:

Patients with current life-threatening infection at time of transplant that would preclude a transplant are excluded.

Concurrent Medication:

Excluded:

• Other anti-retroviral agents.

Patients with current life-threatening infection at time of transplant that would preclude a transplant are excluded.

Patients must be:

• HTLV III antibody positive by ELISA or Western blot or HTLV III viremia.
• At high mortal risk with a diagnosis of AIDS or AIDS Related Complex (ARC).
• Also patient must fall into one of the following categories:
• Have an HIV seronegative identical twin to serve as a bone marrow donor.
• Have documentation of large cell/diffuse histiocytic lymphoma/DPDL.
• Be a good risk candidate for bone marrow transplant.